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binary restenosis
rate(%)
O( 0%)
5(12%)
3
reference MLD stenosis
diameter (mm) (mm) (%)
pre procedure 294 ± 0.37 094 ± 0.28 68.7 ± 9.9
pre-dilatation 2.91 ± 0.36 159 ± 032 45.9 ± 13.5
post stenting 2.89 ± 0.39 269 ± 0.22 59 ± 10.8
next day In ~ 36) 2.88 ± 032 2.64 ± 0.21 8.0± 8.0
1mo FlU (n = 35) 291 ± 0.35 2.57 ± 023 11.2± 8.7
3moF/U(n = 41) 2.84 ± 0.32 2.02 ± 0.52 28.9 ± 17.3
6 mo FlU (n = 15) 2.84 ± 0.32 1.82 ± 0.56 36.6 ± 18.2
Complications
Repeat angioplasty was required in 4 of 8 patients with restenosis. Thus,
the Cordis stent implantation can be achieved with a high degree of technical
and clinical success because of its flexible design and good visibility. Further-
more, its very low complication rates are encouraging. Restenosis rate at 3
months follow-up period is acceptably low.
acutelsubacute occlusion: 0 OInon Q-MI: 1 12%) CABG: 0
death: 0 groin hematoma: 2 (4%) blood transfusions: 3 (5%)
Angiographic findings lesion length: g.O ± 5.4 mm
In order to assess the safety and efficacy of Wiktor Stent (WS) implantation,
data from the French WS registry were reviewed. Between February 1991
and April 1994, 245 stent placements were attempted in 225 patients for
acute or threatening vessel closure after PTCA in 119 (52.9%), nonocclusive
dissection in 11 (4.9%), suboptimal dilatation in 30 (13.3%), restenosis in 55
(24.5%) and de novo lesions in 10 (4.4%). Implanted site was LAD in 34.7%,
RCA in 40.9%, left Circumflex in 16%, left main in 1.3% and saphenous graft
in 7.1 %. Stent placement was successful in 93.8% of patients (pts). Failure
was due to peripheral stent migration in 2 pts, inability to cross the lesion
in 8, non-target placement in one and acute occlusion in 3 others. Ten pts
(4.4%) underwent emergent CABG. Death occurred in 5 pts (2.2%) and was
due to cardiac complications in 3 and intracerebral hemorrhage in 2. Sub-
acute thrombosis occurred in 9 pts (4%). Clinical success rate (procedural
success without in hospital death, CABG or MI) was 86.2%. Vascular com-
plications occurred in 4 pts (1.8%). To date. coronary angiography has been
performed in 120/172 (69.8%) eligible pts and showed restenosis (>50%
stenosis) in 26.7%. Factors associated with restenosis were male gender,
current smoking and site of implantation.
Conclusion: WS implantation is very efficacious in reversing critical situa-
tions after angioplasty while carrying an acceptable risk.
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care. The system can also be accessed remotely via modem to permit its
use as a revascularization "consultant."
Conclusion: This program automatically and objectively determines
ACC/AHA, RAND and RAS revascularization appropriateness ratings. It is a
useful tool for evaluating appropriateness of PTCA or CABG in individual pa-
tients as well as for analyzing patterns of care.
The results of Balloon expandable Micro Stent'" (Applied Vascular Engineer-
ing Canada, Inc) were analyzed. This stent is unique in that it comes pre-
mounted on a balloon in non articulated multiples of 4 mm units. The stent is
available in 4, 8 and 12 mm lengths. The short stent unit length allows it to be
used in short lesions, tortuous anatomy, and for complex situations such as
stent delivery through a deployed stent. 16 lesions in 15 patients (pts) were
treated with Micro stent. A one unit (4 mm) stent was used in 3 lesions, a 2
unit (8 mm) stent in 3 lesions and a 3 unit stent (12 mm) stent in 8 lesions re-
spectively. Indication for stent implantation was elective in 15 lesions and for
acute closure after balloon angioplasty in 1 lesion. Vessel distribution was 8
LCX (50%). 5 RCA (31 %) and 3 LAD (19%). In 8 lesions (50%) other types of
stents (Palmaz-Schatz, Gianturco-Roubin orWiktor stent} were deployed. The
reason for the selection of Micro Stent was failed stent delivery using other
type of stents in 9 (56%). tortuous vessel in 4 lesions and for 3 short lesions.
Stent deployment in 8 (50%) lesions were performed through a previously
deployed stent. There was 1 delivery failure due to a failure to pre dilate the
lesion. Intracoronary ultrasound was performed to confirm the optimal stent
expansion and position. Stent migration was noted in 3 lesions. When stent
expansion was optimized, pts received no anticoagulation and either aspirin
325 mglday or Ticlopidine 500 mglday for 1 month with aspirin 325 mg for
5 days. 13 patients (87%) were treated without anticoagulation after stent
deployment. Ouantitative angiographic (AG) measurements is shown in the
table below:
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There was no stent thrombosis at 1 month follow up.
Conclusions. (1) The Micro stent showed high trackability despite complex
anatomy or delivery failure with other types of stents. (2) Stent delivery to dis-
tal lesions through a deployed stent was successful in all cases. (3) When
optimal Micro stent expansion is achieved. antiplatelet therapy (without anti-
coagulation) is effective in preventing stent thrombosis despite use in small
vessels.
Naoya Hamasaki, Hideyuki Nosaka, Masakiyo Nobuyoshl. Kokura Memorial
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To assess the safety and efficacy of the Cordis stent, implantation was at-
tempted in 63 consecutive patients and 64 lesions from Jan. to Aug. 1994
(mean age: 63 years, % male: 79%, % previous MI: 62%, % multi vessel
disease: 47%). The balloon expandable Cordis stent was made up of a sin-
gle strand, very flexible, radiopaque continuous tantalum wire, and was 3.0
or 3.5 mm in diameter and 18 mm in length. The Cordis stent was implanted
electively in 44 lesions (69%), thirty-four of the 64 (58%) were restenotic le-
sions. Locations of the stented artery were LMT in 1, LAD in 28, LCX in 10
and RCA in 25 lesions (single stealing: 51. multiple stenting: 13,3.0 mm
stent: 39, 3.5 mm stent: 25). Unfavorable angiographic morphology (eccen-
tricity, dissection. calcification. ulceration or bend > 45') was noted in 43
lesions (67%). Delivery success was achieved in 57 lesions (90%). Rescue
stenting with this stent after the placement of a different stent had failed
was successful in 3 lesions. Complications and angiographic findings are as
follows.
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The Wiktor coronary stent has been implanted in 82 lesions in 68 patients.
The indication for stent implantation was 49 elective (57%), 10 threatened
closure (12%), 9 SUboptimal PTCA (11 %), 7 chronic total occlusion (9%), 4
restenosis (5%), and 3 acute occlusion (4%). Vessel distribution was 39 RCA
(48%), 31 LAD (37%) and 12 LCX (15%). Successful stent implantation was
achieved in 77 lesions (94%). Average Wiktor stent per lesion was 1.4 ±
0.8 (range 1 to 4). More than one stent was used in 53 patients (69%). Le-
sion length was 14.8 ± 9.7 mm. Final balloon/vessel ratio was 1.03 ± 0.15.
Maximum inflation pressure was 16 ± 3 atmospheres. There were 5 lesions
that required an additional Palmaz-Schatz stent inside the Wiktor to reinforce
the lumen support. Mild stent structural deformity (expanded strut gap) was
seen in 8 lesions. There were 5 stents with severe stent deformity due to
shrinkage (n = 3) or uncoiling (n = 2). 59 patients (93%) with 72 lesions
(88%) of were treated with only antiplatelet therapy after stent implantation
with intravascular ultrasound guidance. There were 2 CABG due to stent se-
vere stent deformity. One death was due to femoral artery occlusion with
multiple organ failure. To date, 35 of an eligible 59 lesions (59%) received
4-6 months angiographic follow up (F/U)
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There was one stent thrombosis that occurred 8 days after the stent proce-
dure and 5 days after antiplatelet therapy was inadvertently stopped. Wiktor
stent restenosis by ::::50% diameter stenosis was present in 8 patients (23%).
